Virchows Archiv

杂志介绍

Virchows Archiv杂志介绍

《Virchows Archiv》是一本以English为主的未开放获取国际优秀期刊，中文名称Virchow的档案，本刊主要出版、报道医学-PATHOLOGY领域的研究动态以及在该领域取得的各方面的经验和科研成果，介绍该领域有关本专业的最新进展，探讨行业发展的思路和方法，以促进学术信息交流，提高行业发展。该刊已被国际权威数据库SCIE收录，为该领域相关学科的发展起到了良好的推动作用，也得到了本专业人员的广泛认可。该刊最新影响因子为3.4，最新CiteScore 指数为7.4。

本刊近期中国学者发表的论文主要有：

• Survival is associated with repressive histone trimethylation markers in both HR-positive HER2-negative and triple-negative breast cancer patients

  Author: Wang, Bo; Zhou, Meng; Shi, Yue-yu; Chen, Xing-lei; Ren, Yue-xiang; Yang, Yuan-zhong; Tang, Lu-ying; Ren, Ze-fang

• Primary lymphoma of the uterine cervix: a clinicopathologic study of 13 cases with review of additional 54 cases in the literature

  Author: Weng, Xin; Huang, Mayan; Zhang, Meng; Yang, Yajie; Liu, Xia; Huang, Yuhua

• Targeted next-generation sequencing reveals activating CTNNB1 mutations in SMARCA4/BRG1-deficient sinonasal carcinomas: a report of two new cases and a brief review of the literature with an emphasis on histogenesis

  Author: Zhao, Ming; Ma, Tianshi; He, Xianglei; Ge, Minghua

• Bronchial salivary gland-type intraductal carcinoma with KIAA1217::RET gene fusion composed of intercalated and oncocytic components

  Author: Song, Lin; Cheng, Xian-Kui; Yang, Zhen; Ji, Xiao-Bin; Zhou, Xiao-Li; Cheng, Hong-Xia; Lin, Dong-Liang

英文介绍

Virchows Archiv杂志英文介绍

Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.